Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
European Medical Journal2h
Semaglutide Before Bariatric Surgery: Not the Weight Loss Boost Expected
A RETROSPECTIVE study conducted by Mass General Brigham researchers has found that taking semaglutide before bariatric ...
pharmaphorum3m
Novo Nordisk's CagriSema data disappoints investors again
Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
And the award goes to... Ozempic! After the skinniest Oscars ever - all of the stars who've credited weight loss drugs for slimming down (and those who insist they ha…
From the likes of Kathy Bates and Sharon Osbourne to Whoopi Goldberg and Oprah Winfrey, there are a number of stars who have ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
BioSpace8h
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
YourLifeChoices4h
How Ozempic and other GLP-1 agonist drugs turn down ‘food noise’ and cravings
When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but ...
Ozempic parent’s new weight-loss drug works better, but not quite good enough
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.